Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 854 clinical trials
Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells of the mouth or oropharynx. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not known whether giving interleukin-2 with surgery and radiation therapy is more effective than surgery and radiation therapy alone. PURPOSE: This …

x-rays
immunomodulator
interleukin-2
oral cancer
tumor cells
  • 18 views
  • 07 Nov, 2020
  • 1 location
Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

This is a phase II study of OBP-301 with pembrolizumab in advanced gastric and gastroesophageal junction adenocarcinoma that has progressed on at least 2 lines of prior therapy for advanced disease.

  • 15 views
  • 25 Jan, 2021
  • 1 location
Metastasis-directed Therapy in Castration-refractory Prostate Cancer

The aim is to define the postponement of next line systemic treatment (NEST), by the use of metastasis-directed therapy in patients with oligoprogressive castration-refractory prostate cancer. This will be defined by the NEST-free survival. Furthermore the investigators will use 18F PSMA PET-CT as investigational imaging, to assess the predictive value …

metastasis
pet/ct
testosterone level
adenocarcinoma
testosterone
  • 0 views
  • 23 Jan, 2021
Establishing Organoids From Metastatic Pancreatic Cancer Patients the OPT-I Study.

Rationale: Pancreatic adenocarcinoma is a malignancy with a poor prognosis. Resection is the only curative option and still 5-year survival rate is less than 10 percent. However, most patients present with advanced disease and are provided with palliative care. The nature of the tumour and the intense stromal reaction around …

  • 35 views
  • 03 Feb, 2021
  • 1 location
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma

The incorporation of proteasome inhibitors and immunomodulatory drugs into the standard of care has improved the outcome for patients with multiple myeloma (MM) over the past 10 years. However, most patients (>85%) still eventually relapse around 3-4 years after diagnosis, and ultimately die of their disease, despite salvage therapies. Relapse …

line of therapy
bortezomib
dexamethasone
proteasome inhibitor
daratumumab
  • 0 views
  • 23 Jan, 2021
  • 1 location
A Randomised Trial of Cabazitaxel Docetaxel Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis

Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer …

  • 3 views
  • 26 Jan, 2021
  • 2 locations
RAdiotherapy for Metastatic Spinal Cord Compression With Increased Radiation dosES

This clinical study aims to investigate whether high-precision radiotherapy, as supposed, leads to a better control of the irradiated spinal cord metastases when compared to conventional radiotherapy. This means that a progression or recurrence of motor deficits (weakness) of the legs following radiotherapy can be avoided more effectively. Furthermore, the …

  • 0 views
  • 23 Jan, 2021
  • 2 locations
Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT

At the moment there is a lack of data in the setting of oligometastatic PC in particular regarding the interaction between ablative SBRT, ADT and patient's immune system response. The hypothesis underlying this project consists in the idea that the patient's immunological context, RT and ADT may interact in the …

  • 0 views
  • 26 Jan, 2021
  • 1 location
A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer

Induction chemotherapy will be administered every 2 weeks for 6 cycles (about 3 months). Patients who have radiological evidence of progressive disease will be shifted to salvage chemotherapy. Patients who have responsive or stable disease after induction chemotherapy will receive concurrent chemoradiotherapy 3-4 weeks after the last dose of induction …

measurable disease
unresectable pancreatic cancer
chemoradiotherapy
adenocarcinoma
immunostimulant
  • 11 views
  • 07 Nov, 2020
  • 2 locations
Safety and Efficacy of Mesenchymal Stem Cell for Radiation-induced Hyposalivation and Xerostomia in Previous Head and Neck Cancer Patients

The incidence of head and neck cancer is increasing in the Western World, including Denmark. Cancer of the head and neck and its treatment often have a detrimental and lifelong impact on the quality of life of the patients. Radiotherapy is a key component for approximately 80% of all patients …

  • 0 views
  • 05 Mar, 2021
  • 1 location